TY - JOUR
T1 - Multidomain interventions
T2 - state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services—part 4 of 6
AU - Solomon, Alina
AU - Stephen, Ruth
AU - Altomare, Daniele
AU - Carrera, Emmanuel
AU - Frisoni, Giovanni B.
AU - Kulmala, Jenni
AU - Molinuevo, José Luis
AU - Nilsson, Peter
AU - Ngandu, Tiia
AU - Ribaldi, Federica
AU - Vellas, Bruno
AU - Scheltens, Philip
AU - Kivipelto, Miia
AU - on behalf of the European Task Force for Brain Health Services
AU - Abramowicz, Marc
AU - Barkhof, Frederik
AU - Berthier, Marcelo
AU - Bieler, Melanie
AU - Blennow, Kaj
AU - Brayne, Carol
AU - Brioschi, Andrea
AU - Chételat, Gael
AU - Csajka, Chantal
AU - Demonet, Jean-François
AU - Dodich, Alessandra
AU - Dubois, Bruno
AU - Garibotto, Valentina
AU - Georges, Jean
AU - Hurst, Samia
AU - Jessen, Frank
AU - Llewellyn, David
AU - Mcwhirter, Laura
AU - Milne, Richard
AU - Minguillón, Carolina
AU - Miniussi, Carlo
AU - Nilsson, Peter M.
AU - Ranson, Janice
AU - Ritchie, Craig
AU - Solomon, Alina
AU - van Duijn, Cornelia
AU - van der Flier, Wiesje
AU - Visser, Leonie
N1 - Funding Information:
AS receives research funding from the European Research Council grant 804371, Academy of Finland (287490, 294061, 319318), Yrjö Jahnsson Foundation, Finnish Cultural Foundation (Finland), Alzheimerfonden, and Region Stockholm ALF (Sweden).
Funding Information:
GBF received funding from the EU-EFPIA Innovative Medicines Initiatives 2 Joint Undertaking (IMI 2 JU): “European Prevention of Alzheimer’s Dementia consortium” (EPAD, grant agreement number: 115736and “Amyloid Imaging to Prevent Alzheimer’s Disease” (AMYPAD, grant agreement number: 115952), and the Swiss National Science Foundation: “Brain connectivity and metacognition in persons with subjective cognitive decline (COSCODE): correlation with clinical features and in vivo neuropathology” (grant number: 320030_182772).
Funding Information:
GBF reports grants from Alzheimer Forum Suisse, Académie Suisse des Sciences Médicales, Avid Radiopharmaceuticals, Biogen, GE International, Guerbert, Association Suisse pour la Recherche sur l’Alzheimer, IXICO, Merz Pharma, Nestlé, Novartis, Piramal, Roche, Siemens, Teva Pharmaceutical Industries, Vifor Pharma, and Alzheimer’s Association; he has received personal fees from AstraZeneca, Avid Radiopharmaceuticals, Elan Pharmaceuticals, GE International, Lundbeck, Pfizer, and TauRx Therapeutics.
Funding Information:
This paper was the product of a workshop funded by the Swiss National Science Foundation entitled “Dementia Prevention Services” (grant number: IZSEZ0_193593).
Funding Information:
MK receives research funding from the Joint Programme - Neurodegenerative Disease Research (EURO-FINGERS), Academy of Finland (305810, 317465), Swedish Research Council, Center for Innovative Medicine (CIMED) at Karolinska Institutet, Region Stockholm (ALF, NSV), Knut and Alice Wallenberg Foundation, Stiftelsen Stockholms Sjukhem, Konung Gustaf V:s och Drottning Victorias Frimurarstiftelse, Swedish Research Council for Health, and Working Life and Welfare (FORTE).
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12/1
Y1 - 2021/12/1
N2 - Although prevention of dementia and late-life cognitive decline is a major public health priority, there are currently no generally established prevention strategies or operational models for implementing such strategies into practice. This article is a narrative review of available evidence from multidomain dementia prevention trials targeting several risk factors and disease mechanisms simultaneously, in individuals without dementia at baseline. Based on the findings, we formulate recommendations for implementing precision risk reduction strategies into new services called Brain Health Services. A literature search was conducted using medical databases (MEDLINE via PubMed and SCOPUS) to select relevant studies: non-pharmacological multidomain interventions (i.e., combining two or more intervention domains), target population including individuals without dementia, and primary outcomes including cognitive/functional performance changes and/or incident cognitive impairment or dementia. Further literature searches covered the following topics: sub-group analyses assessing potential modifiers for the intervention effect on cognition in the multidomain prevention trials, dementia risk scores used as surrogate outcomes in multidomain prevention trials, dementia risk scores in relation to brain pathology markers, and cardiovascular risk scores in relation to dementia. Multidomain intervention studies conducted so far appear to have mixed results and substantial variability in target populations, format and intensity of interventions, choice of control conditions, and outcome measures. Most trials were conducted in high-income countries. The differences in design between the larger, longer-term trials that met vs. did not meet their primary outcomes suggest that multidomain intervention effectiveness may be dependent on a precision prevention approach, i.e., successfully identifying the at-risk groups who are most likely to benefit. One such successful trial has already developed an operational model for implementing the intervention into practice. Evidence on the efficacy of risk reduction interventions is promising, but not yet conclusive. More long-term multidomain randomized controlled trials are needed to fill the current evidence gaps, especially concerning low- and middle-income countries and integration of dementia prevention with existing cerebrovascular prevention programs. A precision risk reduction approach may be most effective for dementia prevention. Such an approach could be implemented in Brain Health Services.
AB - Although prevention of dementia and late-life cognitive decline is a major public health priority, there are currently no generally established prevention strategies or operational models for implementing such strategies into practice. This article is a narrative review of available evidence from multidomain dementia prevention trials targeting several risk factors and disease mechanisms simultaneously, in individuals without dementia at baseline. Based on the findings, we formulate recommendations for implementing precision risk reduction strategies into new services called Brain Health Services. A literature search was conducted using medical databases (MEDLINE via PubMed and SCOPUS) to select relevant studies: non-pharmacological multidomain interventions (i.e., combining two or more intervention domains), target population including individuals without dementia, and primary outcomes including cognitive/functional performance changes and/or incident cognitive impairment or dementia. Further literature searches covered the following topics: sub-group analyses assessing potential modifiers for the intervention effect on cognition in the multidomain prevention trials, dementia risk scores used as surrogate outcomes in multidomain prevention trials, dementia risk scores in relation to brain pathology markers, and cardiovascular risk scores in relation to dementia. Multidomain intervention studies conducted so far appear to have mixed results and substantial variability in target populations, format and intensity of interventions, choice of control conditions, and outcome measures. Most trials were conducted in high-income countries. The differences in design between the larger, longer-term trials that met vs. did not meet their primary outcomes suggest that multidomain intervention effectiveness may be dependent on a precision prevention approach, i.e., successfully identifying the at-risk groups who are most likely to benefit. One such successful trial has already developed an operational model for implementing the intervention into practice. Evidence on the efficacy of risk reduction interventions is promising, but not yet conclusive. More long-term multidomain randomized controlled trials are needed to fill the current evidence gaps, especially concerning low- and middle-income countries and integration of dementia prevention with existing cerebrovascular prevention programs. A precision risk reduction approach may be most effective for dementia prevention. Such an approach could be implemented in Brain Health Services.
KW - Aging
KW - Alzheimer’s disease
KW - Brain Health Services
KW - Dementia
KW - Dementia risk
KW - Prevention
KW - Risk reduction
UR - http://www.scopus.com/inward/record.url?scp=85116906824&partnerID=8YFLogxK
U2 - 10.1186/s13195-021-00875-8
DO - 10.1186/s13195-021-00875-8
M3 - Review article
C2 - 34635167
SN - 1758-9193
VL - 13
JO - Alzheimer's Research & Therapy
JF - Alzheimer's Research & Therapy
IS - 1
M1 - 171
ER -